AMPLIFON SPA

Amplifon manufactures mobile applications specifically designed as remote controls for hearing aid and implant systems. These apps allow users to adjust volume, switch programs, and manage connectivity directly from their smartphones. The focus is on digital solutions that enhance the functionality of hearing aids or cochlear implants, ensuring users can customize their experience without physical controls.

Amplifon is based in the United States, which means its devices are developed and regulated under U.S. medical device compliance standards. Since these products are classified as software-as-a-medical-device applications, they must meet FDA requirements for digital health tools, including safety, performance, and usability criteria. The U.S. regulatory framework ensures these apps are designed to operate safely alongside hearing aids or implants.

Amplifon’s devices are listed in the FDA’s Unique Device Identifier (UDI) database. The UDI system provides a standardized way to identify medical devices, ensuring transparency and traceability in the regulatory and healthcare systems. Listing in this database helps healthcare providers, insurers, and regulators quickly locate and verify the device’s details, such as its classification and compliance status.

Amplifon’s remote control apps for hearing aids and implants are classified as FDA Class II devices. This classification is typically assigned to devices that pose moderate risk and require special controls to ensure their safety and effectiveness. While Class II devices still undergo rigorous review, they may have established standards or post-market surveillance requirements to maintain compliance, ensuring these digital tools meet necessary performance and safety benchmarks.